Gastroenterology
Volume 128, Issue 3 , Pages 541-551 , March 2005

Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles

  • Liam O’Mahony

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • ,
  • Jane McCarthy

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • ,
  • Peter Kelly

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • ,
  • George Hurley

      Affiliations

    • Procter & Gamble Company, Mason, Ohio
    • ,
  • Fangyi Luo

      Affiliations

    • Procter & Gamble Company, Mason, Ohio
    • ,
  • Kersang Chen

      Affiliations

    • Procter & Gamble Company, Mason, Ohio
    • ,
  • Gerald C. O’Sullivan

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • ,
  • Barry Kiely

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • Alimentary Health Ltd, Kinsale, Cork, Ireland
    • ,
  • J. Kevin Collins

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • ,
  • Fergus Shanahan

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • ,
  • Eamonn M.M. Quigley

      Affiliations

    • Alimentary Pharmabiotic Centre, University College Cork, Cork, Ireland
    • Corresponding Author InformationAddress requests for reprints to: Eamonn M. M. Quigley, MD, Alimentary Pharmabiotic Center, Department of Medicine, Clinical Sciences Building, Cork University Hospital, Cork, Ireland; fax: (353) 21-490-1289.

Received 10 June 2004 ,Accepted 11 November 2004.

References 

  1. Brandt LJ, Locke GR, Olden K, Quigley E, Schoenfeld P, Schuster M, et al. An evidence-based approach to the management of irritable bowel syndrome in North America . Am J Gastroenterol . 2002;97(Suppl):S1–S26
  2. Drossman DA , Camileri M , Mayer EA , Whitehead WE . AGA technical review on irritable bowel syndrome . Gastroenterology . 2002;123:2108–2131
  3. Thompson WG , Longstreth GF , Drossman DA , Heaton KW , Irvine EJ , Muller-Lissner SA . Functional bowel disorders and functional abdominal pain . Gut . 1999;45(Suppl II):II43–II47
  4. Thompson WG , Heaton KW , Smyth GT , Smyth C . Irritable bowel syndrome in general practice (prevalence, characteristics, and referral) . Gut . 2000;46:78–82
  5. Hungin APS , Whorwell PJ , Tack J , Mearin F . The prevalence, patterns and impact of irritable bowel syndrome (an international survey of 40,000 subjects) . Aliment Pharmacol Ther . 2003;17:643–650
  6. Jailwala J , Imperiale TF , Kroenke K . Pharmacologic treatment of the irritable bowel syndrome (a systematic review of randomized, controlled trials) . Ann Intern Med . 2000;133:136–147
  7. Jones J, Boorman J, Cann P, Forbes A, Gomborone J, Heaton K, et al. British Society of Gastroenterology guidelines for the management of the irritable bowel syndrome . Gut . 2000;47(Suppl II):ii1–ii19
  8. Akehurst R , Kaltenthaler E . Treatment of irritable bowel syndrome (a review of randomised controlled trials) . Gut . 2001;48:272–282
  9. Camilleri M . Management of the irritable bowel syndrome . Gastroenterology . 2001;120:652–668
  10. Talley NJ . Pharmacologic therapy for the irritable bowel syndrome . Am J Gastroenterol . 2003;98:750–758
  11. Poynard T , Naveau S , Mory B , Chaput JC . Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome . Aliment Pharmacol Ther . 1994;8:499–510
  12. Quigley EMM . Current concepts of the irritable bowel syndrome . Scand J Gastroenterol . 2003;38(Suppl 237):1–8
  13. Mayer EA , Collins SM . Evolving pathophysiological models of functional gastrointestinal disorders . Gastroenterology . 2002;122:2032–2048
  14. McKendrick MW , Read MW . Irritable bowel syndrome—post-salmonella infection . J Infect . 1994;29:1–3
  15. Neal KR , Hebdon J , Spiller R . Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome . BMJ . 1997;314:779–782
  16. Gwee K-A, Leong Y-L, Graham C, McKendrick MW, Collins SM, Walters SJ, et al. The role of psychological and biological factors in post-infective gut dysfunction . Gut . 1999;44:400–406
  17. Garcia Rodriguez LA , Ruigomez A . Increased risk of irritable bowel syndrome after bacterial gastroenteritis (cohort study) . BMJ . 1999;318:565–566
  18. Spiller RC . Estimating the importance of infection in IBS . Am J Gastroenterol . 2003;98:238–241
  19. Spiller RC, Jenkins D, Thornley JP, Hebden JM, Wright T, Skinner M, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome . Gut . 2000;47:804–811
  20. Dunlop SP , Jenkins D , Neal KR , Spiller RC . Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS . Gastroenterology . 2003;125:1651–1659
  21. Cumberland P, Sethi D, Roderick PJ, Wheeler JG, Cowden JM, Roberts JA, et al. The infectious intestinal disease study of England (a prospective evaluation of symptoms and health care use after an acute episode) . Epidemiol Infect . 2003;130:453–460
  22. Collins SM . A case for an immunological basis for irritable bowel syndrome . Gastroenterology . 2002;122:2078–2080
  23. Chadwick V, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, et al. Activation of the mucosal immune system in irritable bowel syndrome . Gastroenterology . 2002;122:1778–1783
  24. Tornblom H , Lindberg G , Nyberg B , Veress B . Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome . Gastroenterology . 2002;123:1972–1979
  25. O’Sullivan M, Clayton N, Breslin NP, Harman I, Bountra C, McLaren A, et al. Increased mast cells in the irritable bowel syndrome . Neurogastroenterol Motil . 2000;12:449–457
  26. Gonsalkorale WM , Perrey C , Pravica V , Whorwell PJ , Hutchinson IV . Interleukin 10 genotypes in irritable bowel syndrome (evidence for an inflammatory component?) . Gut . 2003;52:91–93
  27. Gwee K-A, Collins SM, Read NW, Ranjnakova A, Deng Y, Graham JC, et al. Increased rectal mucosal expression of interleukin 1beta in recently acquired post-infectious irritable bowel syndrome . Gut . 2003;52:523–526
  28. Pimentel M , Chow EJ , Lin HC . Eradication of small bowel bacterial overgrowth reduces symptoms of irritable bowel syndrome . Am J Gastroenterol . 2000;95:3503–3506
  29. Pimentel M , Chow E , Lin H . Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome (a double-blind, randomized, placebo-controlled study) . Am J Gastroenterol . 2003;98:412–419
  30. Tursi A , Brandimarte G , Giorgetti GM . High prevalence of small intestinal bacterial overgrowth in celiac patients with persistence of gastrointestinal symptoms after gluten withdrawal . Am J Gastroenterol . 2003;98:839–843
  31. O’Leary C , Quigley EMM . Small bowel bacterial overgrowth, celiac disease and IBS (what are the associations?) . Am J Gastroenterol . 2003;98:720–722
  32. Shanahan F . Therapeutic manipulation in gut flora . Science . 2000;289:1311–1312
  33. Collins SM . The immunomodulation of enteric neuromuscular function (implications for motility and inflammatory disorders) . Gastroenterology . 1996;111:1683–1699
  34. Gorbach SL . Probiotics in the third millennium . Dig Liver Dis . 2002;34(Suppl 2):S2–S7
  35. Isolauri E , Kirjavainen PV , Salminen S . Probiotics (a role in the treatment of intestinal infection and inflammation?) . Gut . 2002;50:iii54–iii59
  36. Von Wright A , Salminen S . Probiotics (established effects and open questions) . Eur J Gastroenterol Hepatol . 1999;11:1195–1198
  37. O’Mahony L, Feeney M, O’Halloran S, Murphy L, Kiely B, Fitzgibbon J, et al. Probiotic impact on microbial flora, inflammation, and tumour development in IL-10 knockout mice . Aliment Pharmacol Ther . 2001;15:1219–1225
  38. McCarthy J, O’Mahony L, O’Callaghan L, Sheil B, Vaughan EE, Fitzsimons N, et al. Double blind, placebo controlled trial of two probiotic strains in interleukin 10 knockout mice and mechanistic link with cytokine balance . Gut . 2003;52:975–980
  39. Bradley HK , Wyatt GM , Bayliss CE , Hunter JO . Instability in the faecal flora of a patient suffering from food-related irritable bowel syndrome . J Med Microbiol . 1987;23:29–32
  40. Balsari A , Ceccarelli A , Dubini F , Fesce E , Poli G . The fecal microbial population in the irritable bowel syndrome . Microbiologica . 1982;5:185–194
  41. King TS , Elia M , Hunter JO . Abnormal colonic fermentation in irritable bowel syndrome . Lancet . 1998;352:1187–1189
  42. Jiang T , Savaiano DA . Modification of colonic fermentation by bifidobacteria and pH in vitro (impact on lactose metabolism, short-chain fatty acid, and lactate production) . Dig Dis Sci . 1997;42:2370–2377
  43. Ouwehand AC , Lagstrom H , Suomalainen T , Salminen S . Effect of probiotics on constipation, fecal azoreductase activity and fecal mucin content in the elderly . Ann Nutr Metab . 2002;46:159–162
  44. Halpern GM , Prindiville T , Blankenburg M , Hsia T , Gershwin ME . Treatment of irritable bowel syndrome with Lacteol Fort (a randomized, double-blind, cross-over trial) . Am J Gastroenterol . 1996;91:1579–1585
  45. Nobaek S , Johansson ML , Molin G , Ahrne S , Jeppsson B . Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome . Am J Gastroenterol . 2000;95:1231–1238
  46. O’Sullivan MA , O’Morain CA . Bacterial supplementation in the irritable bowel syndrome (A randomised double-blind placebo-controlled crossover study) . Dig Liver Dis . 2000;32:302–304
  47. Brigidi P , Vitali B , Swennen E , Bazzocchi G , Matteuzzi D . Effects of probiotic administration upon the composition and enzymatic activity of human fecal microbiota in patients with irritable bowel syndrome or functional diarrhea . Res Microbiol . 2001;152:735–741
  48. Niedzielin K , Kordecki H , Birkenfeld B . A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome . Eur J Gastroenterol Hepatol . 2001;13:1143–1147
  49. Sen S , Mullan MM , Parker TJ , Woolner JT , Tarry SA , Hunter JO . Effect of Lactobacillus plantarum 299v on colonic fermentation and symptoms of irritable bowel syndrome . Dig Dis Sci . 2002;47:2615–2620
  50. Bazzocchi G , Gionchetti P , Almerigi PF , Amadini C , Campieri M . Intestinal microflora and oral bacteriotherapy in irritable bowel syndrome . Dig Liver Dis . 2002;34(Suppl 2):s48–s53
  51. Adler SN , Jacob H , Eliakim R . The probiotic agent E-Coli strain ATCC20226 has a healing effect on proximal inflammation of the small bowel . (abstr) Gastroenterology . 2002;122:A527
  52. Parker P , McNaught CE , Anderson ADG , Mitchell CJ , MacFie J . Synbiotic in irritable bowel syndrome (a double blind prospective randomised controlled trial) . (abstr) Gut . 2003;52:A11
  53. Kim HJ, Camilleri M, McKinzie S, Lempke MB, Burton DD, Thomforde GM, et al. A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome . Aliment Pharmacol Ther . 2003;17:895–904
  54. Barbara G , Corinaldesi R . Probiotics (could they turn out to be ineffective in irritable bowel syndrome?) . Dig Liver Dis . 2000;32:294–301
  55. Hamilton-Miller JMT . Probiotics in the management of irritable bowel syndrome (a review of clinical trials) . Microb Ecol Health Dis . 2001;13:212–216
  56. Thompson WG . Probiotics for irritable bowel syndrome (a light in the darkness?) . Eur J Gastroenterol Hepatol . 2001;13:1135–1136
  57. Madden JA , Hunter JO . A review of the role of the gut microflora in irritable bowel syndrome and the effects of probiotics . Br J Nutr . 2002;88(Suppl 1):S67–S72
  58. Floch MH . Probiotics, irritable bowel syndrome, and inflammatory bowel disease . Curr Treat Options Gastroenterol . 2003;6:283–288
  59. Dunne C, O’Mahony L, Murphy L, Thornton G, Morrissey D, O’Halloran S, et al. In vitro selection criteria for probiotic bacteria of human origin (correlation with in vivo findings) . Am J Clin Nutr . 2001;73:886S–892S
  60. Dunne C, Murphy L, Flynn S, O’Mahony L, O’Halloran S, Feeney M, et al. Probiotics: from myth to reality (Demonstration of functionality in animal models of disease and in human clinical trials) . Antonie Van Leeuwenhoek . 1999;76:279–292
  61. Collins JK, Dunne C, Murphy L, Morrissey D, O’Mahony L, O’Sullivan E, et al. A randomised controlled trial of a probiotic Lactobacillus strain in healthy adults (assessment of its delivery, transit, and influence on microbial flora and enteric immunity) . Microb Ecol Health Dis . 2002;14:81–89
  62. Veldhuyzen Van Zanten SJ , Talley NJ , Bytzer P , Klein KB , Whorwell PJ , Zinsmeister AR . Design of trials for functional gastrointestinal disorders . Gut . 1999;45(Suppl 2):II68–II77
  63. Heaton KW , O’Donnell LJ . An office guide to whole-gut transit time (Patients’ recollection of their stool form) . J Clin Gastroenterol . 1994;19:28–30
  64. Drossman DA, Patrick DL, Whitehead WE, Toner BB, Diamant NE, Hu Y, et al. Further validation of the IBS-QOL (a disease-specific quality-of-life questionnaire) . Am J Gastroenterol . 2000;95:999–1007
  65. Boyum A . Separation of leukocytes from blood and bone marrow . Scand J Clin Lab Invest Suppl . 1968;97:7
  66. Cremonini F , Delgado-Aros S , Camilleri M . Efficacy of alosetron in irritable bowel syndrome (a meta-analysis of randomized controlled trials) . Neurogastroenterol Motil . 2003;15:79–86
  67. Muller-Lissner SA, Fumagalli I, Bardhan KD, Pace F, Pecher E, Nault B, et al. Tegaserod, a 5-HT receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation . Aliment Pharmacol Ther . 2001;15:1655–1666
  68. Kellow J, Lee OY, Chang FY, Thongsawat S, Mazlam MZ, Yuen H, et al. An Asia-Pacific, double blind, placebo-controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome . Gut . 2003;52:671–676
  69. Perdigon G , Alvarez S , Nader DE , Macias ME , Roux ME , de Ruiz Holgado AP . The oral administration of lactic acid bacteria increases the mucosal immunity in response to enteropathogens . J Food Protection . 1990;53:404–440
  70. Rolfe RD . The role of probiotic cultures in the control of gastrointestinal health . J Nutr . 2000;130(2S Suppl):396S–402S
  71. Duffy LC , Leavens A , Griffiths E , Dryja D . Perspectives on bifidobacteria as biotherapeutic agents in gastrointestinal health . Dig Dis Sci . 1999;44:1499–1505
  72. Marteau P , Seksisk P , Jian R . Probiotics and intestinal health effects (a clinical perspective) . Br J Nutr . 2002;88(Suppl 1):S51–S57
  73. Fooks LJ , Gibson GR . Probiotics as modulators of the gut flora . Br J Nutr . 2002;88(Suppl 1):S39–S49
  74. Cremonini F, Di Caro S, Santarelli L, Gabrielli M, Candelli M, Nista EC, et al. Probiotics in antibiotic-associated diarrhoea . Dig Liver Dis . 2002;34:S78–S80
  75. Byrne F, Murphy LM, Binder S, Collins JK, O’Sullivan GC, Shanahan F, Aranda R. Prevention of wasting and colitis in SCID mice reconstituted with CD4+ and RB high cells by the administration of the probiotic Bifidobacterium longum infantis. (in press)
  76. Rachmilewitz D, Katakura K, Karmeli F, Hayashi T, Reinus C, Rudensky B, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis . Gastroenterology . 2004;126:520–528
  77. Jijon H, Backer J, Diaz H, Yeung H, Thiel D, McKagney C, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function . Gastroenterology . 2004;126:1358–1373
  78. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome . Gastroenterology . 2004;126:693–702
  79. Greenwood-van Meerveld B, Johnson AC, Kajs T, Charbonnealu D, Poehner R, Chen K-S, et al. Probiotic bacteria normalize post inflammatory visceral hyperalgesia in rats (abstr) . Gastroenterology . 2002;122:A476
  80. Lamine F , Cauquil E , Eutamene H , Fioramonti J , Bueno L , Theodorou V . Lactobacillus farciminis treatment reduces sensitivity to rectal distension in rats (involvement of nitric oxide) . (abstr) Gastroenterology . 2003;122:A476
  81. Quigley EMM . The role of gas in IBS . In:  Camilleri M ,  Spiller RC editor. Irritable bowel syndrome. Diagnosis and treatment . Philadelphia, PA: Saunders; 2002;p. 77–84
  82. Quigley EMM . From comic relief to real understanding; how intestinal gas causes symptoms . Gut . 2003;52:1659–1661
  83. Serra J , Azpiroz F , Malagelada JR . Impaired transit and tolerance of gas in the irritable bowel syndrome . Gut . 2001;48:14–19
  84. Alender M, Satokari R, Korpela R, Saxelin M, Vilpponen-Salmela T, Mattila-Sandholm T, et al. Persistence of colonization of human colonic mucosa by a probiotic strain, Lactobacillus rhamnosus GG, after oral consumption . Appl Environ Microbiol . 1999;65:351–354
  85. Zoetendal EG , von Wright A , Vilpponen-Salmela T , Ben-Amor K , Akkermans ADL , de Vos WM . Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces . Appl Environ Microbiol . 2002;68: 3410–3407
  86. Uribe A , Alam M , Johansson O , Midtvedt T , Theodorsson E . Microflora modulates endocrine cells in the gastrointestinal mucosa of the rat . Gastroenterology . 1994;107:1259–1269

 Supported in part by Science Foundation Ireland in the form of a centre grant (Alimentary Pharmabiotic Centre), the Health Research Board of Ireland, the Higher Education Authority of Ireland, and the European Union (PROGID QLK-2000-00563). The authors are affiliated with a multidepartmental university campus company (Alimentary Health Ltd) that investigates host-flora interactions and the therapeutic manipulation of these interactions in various human and animal disorders. The content of this report was neither influenced nor constrained by this fact.

PII: S0016-5085(04)02155-9

doi: 10.1053/j.gastro.2004.11.050

Gastroenterology
Volume 128, Issue 3 , Pages 541-551 , March 2005

Article Tools

* Image Usage & Resolution